期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

iNKT细胞多样性调节机制及其在疾病中的作用 被引量：1

原文传递
导出
作者 陈钰
机构地区 解放军总医院免疫学教研室
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2009年第1期84-86,共3页 Chinese Journal of Cellular and Molecular Immunology
基金 国家自然科学基金资助项目(30671981 30571650) 国家高技术研究发展计划(863)资助项目(2006AA02Z462)
关键词 INKT细胞 肿瘤 糖尿病 免疫性疾病
分类号 R392.11 [医药卫生—免疫学]
  • 相关文献

参考文献17

  • 1Taniguchi M. A novel lymphocyte-NKT[ J]. JSI News Letter, 2000, 8 (1): 15-16.
  • 2Barbara A, Sullivan, Mitchell K. Activation or anergy: NKT cells are stunned by α-galactosylcermide [ J ]. J Clini lnves, 2005, 115 ( 9 ) : 2328 - 2329.
  • 3Albert B, Paul B. Savage and Luc Teyton The biology of NKT cells [J]. Annu Rev Immunol, 2007, 25(4) : 297 -336.
  • 4Van Rhijn I, Koets AP, Im JS, et al. The bovine CD1 family contains group 1 CD1 proteins but no functional CD1d[ J]. J Immunol, 2006, 176(8) : 4888 - 4893.
  • 5Sharif S, Arreaza GA, Zucker P, et al. Activation of natural killer T ceils by alphagalactosylcermide treatment prevents the onset and recurrence of autoimmune type 1 diabetes [ J ]. Nat Med, 2001,7 (9) : 1057 - 1062.
  • 6Hong S , Wilson MT, Serizawa I, et al. The natural killer T-cell ligand alpha-galactosylcermide prevents the autoimmune diabetes in nonobese diabetic mice[J]. Nat Med, 2001, 7(9) : 1052 -1056.
  • 7Hayakawa Y, Godfrey DI, Smyth MJ. Alpha-galactosylcermide: potential immunomodulatory activity and future application [ J ]. Curr Med Chem, 2004, 11(2) : 241 -252.
  • 8Mattner J, Debord LK, Ismail N, et al. Exogenous angendogenous glycolipid antigens activate NKT cells during microbial infections [ J ]. Nature, 2005, 434(7032) : 525 -529.
  • 9Seino K, Taniguchi M. Functionally distinct NKT cell subsets and subtypes[J]. JEM, 2005, 202(12) : 1623 - 1626.
  • 10Ken-ichiro S, Shinichiro M, Takehiko F, et al. Natural killer T cell- mediated antitumor immune responses and their clinical applications [J]. Cancer Sci, 2006, 97(9) :807 -812.

同被引文献39

  • 1Eisenbarth S C,Colegio O R,O‘Connor W,et al.Crucial role for the Nalp3inflammasome in theimmunostimulatory properties of aluminium adjuvants. Nature . 2008
  • 2Freund J.The mode of action of immunologicaladjuvants. Advances in Tuberculosis Research . 1956
  • 3Du C,Nilsson S,Lu H,et al.Immunogenicity of thePlasmodium falciparum Pf332-DBL domain incombination with different adjuvants. Vaccine . 2010
  • 4Viola S,Vicente D,Andreas W,et al.Safety of MF-59TM adjuvant. Vaccine . 2008
  • 5Mosca F,Tritto E,Muzzi A,et al.Molecular andcellular signatures of human vaccine adjuvants. Proceedings of the National Academy of Sciences of the United States of America . 2008
  • 6Geert L R.Prepandemic H5N1influenza vaccineadjuvanted with AS03:a review of the pre-clinicaland clinical data. Expert Opin Biol Th . 2009
  • 7Sun H X,Xie Y,Ye Y P.ISCOMs andISCOMATRIXTM. Vaccine . 2009
  • 8Sforcin J M.Propolis and the immune system. JEthnopharmacol . 2007
  • 9Fan Y P,Hu Y L,Wang D Y,et al.Epimediumpolysaccharide and propolis flavone cansynergistically stimulate lymphocyte proliferation invitro and enhance the immune responses to NDvaccine in chickens. International Journal of Biological Macromolecules . 2010
  • 10Norell H,Poschke I,Charo J,et al.Vaccinationwith a plasmid DNA encoding HER-2/neu togetherwith low doses of GM-CSF and IL-2in patients withmetastatic breast carcinoma:a pilot clinical trial. Journal of Translational Medicine . 2010

引证文献1

二级引证文献6

细胞与分子免疫学杂志
2009年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部